Perspective Therapeutics, Inc. (NYSE:CATX) has announced encouraging interim results from its ongoing Phase 1/2a clinical ...

The firm has inked a debt financing agreement with Blue Owl Capital and will use the funds to launch ITM-11 in the US market following approval.

This research article is published in the Case Reports in Clinical Radiology, published by Scientific Scholar.Neuroendocrine tumours (NETs) affecting the extrahepatic bile ducts are ...